每经AI快讯，爱美客（300896.SZ）1月30日在投资者互动平台表示，公司经销的肉毒毒素产品最近取得 药品注册证书，公司正在制定相关的销售策略，关于产品销售情况敬请关注公司公告。 （文章来源：每日经济新闻） ...

从产品矩阵角度，爱美客此前已拥有"嗨体""濡白天使"等多个行业现象级产品，填补了不同领域的空 白。如今以PDLLA为核心技术的AestheFill产品销售限制得以解除，市场化推广进程重回正轨。爱美客 在中国医美市场深耕多年所建立的庞大销售网络，将实现产品矩阵的完善与渠道协同，开辟第二增长曲 线，同时契合大健康与颜值管理的消费趋势。 截至目前，韩国REGEN公司旗下AestheFill产品和PowerFill产品已积累了多年的国际市场安全性及有效 性数据。这一全球市场准入资质与临床背书，为爱美客旗下产品的出海提供了国际化平台。通过借鉴 AestheFill产品的全球分销网络与国际注册经验，能够显著加快爱美客布局海外市场的进程。 展望未来，通过技术协同、渠道共振与品牌强化，AestheFill产品有望与爱美客现有产品线产 生"1+1>2"的协同效应。爱美客对REGEN公司的收购，不仅仅能提升业绩盈利能力，更可能开启公司发 展的新阶段。 随着中国医美市场从高速增长转向高质量、规范化发展，拥有完整产品矩阵、强大研发实力、合规经营 体系以及清晰国际化路径的头部企业，将持续享有结构性优势。爱美客在此次法律博弈中取得的阶段 ...

Core Insights - The domestic medical beauty industry is undergoing a structural transformation in 2025, shifting from a "seller's market" to a "buyer's market" due to an increase in the supply of upstream products [1] - The approval of 52 new Class III medical device registrations in 2025 indicates a significant change in the supply-demand relationship within the industry [1] - Upstream manufacturers are compelled to adjust their competitive strategies, focusing on technological innovation, product iteration speed, and commercialization capabilities [1][4] Upstream Manufacturers - The competition among upstream manufacturers is intensifying as the medical beauty market continues to expand and diversify, with the industry size surpassing 300 billion yuan [3] - The light medical beauty market is expected to grow at a compound annual growth rate of over 20% in the next five years, becoming the mainstream segment [3] - Hyaluronic acid, botulinum toxin, collagen, and regenerative materials are projected to dominate the injection materials market in 2024, with respective market shares of 36%, 29%, 19%, and 16% [3] Product Supply Expansion - In 2025, 25 new Class III medical device registrations for hyaluronic acid products were approved, alongside approvals for collagen products, youth needles, and new materials like agarose and calcium phosphate [4] - Manufacturers are shifting from a "follow the trend" model to focusing on product innovation and expanding new indications, particularly in women's health-related aesthetics [4][5] Competitive Landscape - The competition is expected to transition from merely obtaining licenses to a focus on core technology, research efficiency, and understanding end-user needs [5] - The relationship between upstream manufacturers and downstream medical beauty institutions is evolving into a mutually beneficial partnership rather than a zero-sum game [6] Downstream Institutions - The approval of 52 new Class III medical device registrations has provided downstream institutions with greater product selection and negotiating power with upstream manufacturers [6] - New Oxygen's introduction of competitively priced products has sparked controversy among upstream manufacturers, highlighting the ongoing price competition in the market [6] Market Dynamics - Public hospitals are increasingly entering the medical beauty sector, with 203 hospitals opening or establishing medical beauty departments in 2025, a 229% increase from the previous year [8] - Major internet platforms like Meituan and Tmall are leveraging their traffic advantages to enhance the medical beauty sector, intensifying market competition [8] - The future of the medical beauty industry is expected to be characterized by a diverse and competitive landscape, where trust and professional credibility are crucial for consumer acceptance [8]

证券之星消息，1月30日医疗美容板块较上一交易日下跌3.14%，爱美客领跌。当日上证指数报收于 4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.07 | -1.92% | 12.54万 | 3883.90万 | | 920982 | 锦波生物 | 221.39 | -2.42% | 7085.98 | 1.58亿 | | 688363 | 华熙生物 | 44.83 | -3.20% | 4.64万 | 2.10亿 | | 300896 | 爱美客 | 139.73 | -3.22% | 3.76万 | 5.31亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出7658.45万元，游资资金净流入4438.38万元，散户 资金净流入3220.06万元。医疗美容板块个股资金流向见下表： | 代码 | | | | 名称 ｜主力净流入（元）｜主力净占比｜ ...

证券代码：300896 证券简称：爱美客 公告编号：2026-002 号 爱美客技术发展股份有限公司 关于公司控股子公司 REGEN Biotech, Inc.重大仲裁的进展公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 重要提示： 1.2025 年 9 月 10 日，深圳国际仲裁院（以下简称"深国仲"）紧急仲裁员 曾就达透医疗器械（上海）有限公司（以下简称"达透公司"）提出的临时措施 申请作出《深圳国际仲裁院决定书》（（2025）深国仲涉外受 8781 号），决定 REGEN Biotech, Inc.（以下简称"REGEN 公司"）在本案仲裁裁决作出前，不 得自行在中国国内销售 AestheFill 产品、不得否认达透公司是 AestheFill 产 品在中国国内的独家经销商、不得拒绝并应继续向达透公司按协议约定供应该产 品。2026 年 1 月 29 日，REGEN 公司收到深国仲作出的《仲裁庭关于〈撤销临时 措施决定申请〉的决定》，仲裁庭决定不再实施由紧急仲裁员于 2025 年 9 月 10 日作出的前述《深圳国际 ...

证券日报网讯1月29日，爱美客（300896）在互动平台回答投资者提问时表示，公司2025年整体经营业 绩及核心产品数据尚处年报编制阶段，将按监管要求在2025年年报中披露。 ...

Core Insights - The medical beauty sector experienced a rise of 2.96% on January 29, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Beauty Sector Performance - Ai Meike (300896) closed at 144.38, with a gain of 4.53%, trading volume of 56,700 shares, and a transaction value of 803 million [1] - Huaxi Biological (688363) closed at 46.31, up 1.47%, with a trading volume of 45,900 shares and a transaction value of 211 million [1] - Jinbo Biological (920982) closed at 226.88, up 1.35%, with a trading volume of 8,287 shares and a transaction value of 1.86 billion [1] - ST Meigu (000615) closed at 3.13, down 1.26%, with a trading volume of 103,100 shares and a transaction value of 32.32 million [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 105 million from main funds, while retail investors experienced a net outflow of 33.44 million [1] - Ai Meike had a main fund net inflow of 103 million, representing 12.77%, with retail outflows of 38.71 million [2] - Huaxi Biological had a main fund net inflow of 10.25 million, representing 4.86%, with retail outflows of 1.15 million [2] - Jinbo Biological had a main fund net inflow of 9.45 million, representing 5.09%, with retail inflows of 1.25 million [2] - ST Meigu had a main fund net outflow of 7.90 million, representing -24.43%, with retail inflows of 4.02 million [2]

Core Viewpoint - Aimeike's stock price has shown a slight decline this year, with a recent increase of 2.01% on January 29, 2025, but overall performance indicates a downward trend in the past months, raising concerns about its financial health and market position [1][2]. Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%. The net profit attributable to shareholders was 1.093 billion yuan, down 31.05% compared to the previous year [2]. - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion yuan, with 3.012 billion yuan distributed over the last three years [3]. Shareholder and Market Activity - As of January 20, 2025, Aimeike had 61,700 shareholders, an increase of 0.42% from the previous period. The average number of circulating shares per shareholder decreased by 0.42% to 3,379 shares [2]. - On January 29, 2025, Aimeike's stock price was 140.89 yuan per share, with a total market capitalization of 42.632 billion yuan. The trading volume was 314 million yuan, with a turnover rate of 1.08% [1]. Business Overview - Aimeike, established on June 9, 2004, and listed on September 28, 2020, specializes in the research, production, and sales of biomedical soft tissue repair materials. Its main revenue sources include solution injection products (57.27%), gel injection products (37.97%), and others [1]. - The company operates within the beauty care and medical aesthetics industry, focusing on medical beauty consumables, and is associated with concepts such as weight loss drugs and cosmetics [1]. Institutional Holdings - As of September 30, 2025, Aimeike's top ten circulating shareholders included Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao Zhongzheng Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3].

（编辑 姚尧） 证券日报网讯 1月28日，爱美客在互动平台回答投资者提问时表示，公司新品的终端销售、复购率、医 院进货数据等涉及商业和具体经营数据，公司未有单独的披露数据。公司严格按照法律法规的要求履行 信披义务。 ...

Market Overview - The medical beauty sector experienced a decline of 1.57% on January 28, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - *ST Meigu closed at 3.17, down 0.63% with a trading volume of 66,700 shares and a turnover of 21.20 million yuan [1] - Aimeike closed at 138.12, down 1.56% with a trading volume of 29,800 shares and a turnover of 413 million yuan [1] - Huaxi Biological closed at 45.64, down 1.70% with a trading volume of 28,800 shares and a turnover of 13.20 million yuan [1] - Jinbo Biological closed at 223.85, down 1.97% with a trading volume of 7,323 shares and a turnover of 165 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 49.81 million yuan from main funds, while retail investors had a net inflow of 55.20 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 1.98 million yuan, retail net inflow of 1.61 million yuan [2] - Huaxi Biological: Main funds net outflow of 9.06 million yuan, retail net inflow of 3.16 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.03 million yuan, retail net inflow of 0.38 million yuan [2] - Aimeike: Main funds net outflow of 38.77 million yuan, retail net inflow of 50.43 million yuan [2]